'Biomarkers definitions working group' diaporamas de présentation

563 views • 42 slides

Statistical challenges in the validation of surrogate endpoints

Statistical challenges in the validation of surrogate endpoints. Marc Buyse International Drug Development Institute (IDDI), Brussels Limburgs Universitair Centrum, Diepenbeek, Belgium marc.buyse@iddi.com FDA Industry Workshop, September 22-23, 2004. Outline. Need for surrogates

546 views • 35 slides

Patient Selection Biomarkers in Drug Development: A first step towards individualized therapy Michael Ostland Genentech

Patient Selection Biomarkers in Drug Development: A first step towards individualized therapy Michael Ostland Genentech BioOncology April 21, 2005. Outline. Background Some Challenges of a Drug Development Program that includes Biomarkers Decision Making Logistical and Technical

545 views • 31 slides

Patient Selection Markers in Drug Development Programs

360 views • 19 slides